# DSIP: Research Overview — Peptide Ways > A literature summary of DSIP (Delta Sleep-Inducing Peptide / Emideltide): its discovery, the unresolved receptor question, early human insomnia data, neuroendocrine and neuroprotective findings, and an honest look at community experience. Delta Sleep-Inducing Peptide — a naturally occurring nonapeptide that has been studied since 1977 and still has no identified receptor, no confirmed mechanism, and an inconsistent record in people. ## The short version DSIP stands for **Delta Sleep-Inducing Peptide**. It is a naturally occurring chain of nine amino acids, first isolated from the blood of sleeping rabbits in 1977 and named because infusing it into rabbit brains enhanced the slow, deep brain waves associated with restorative sleep [6]. The INN (international non-proprietary name) registered for it is Emideltide, though no Emideltide product has ever been approved or marketed anywhere. Here is the honest part. Forty-plus years of research have not answered the most basic questions about DSIP. No receptor for it has been identified. No gene encoding it or a precursor has been found. A landmark 2006 review called it a "still unresolved riddle" whose sleep evidence is "extremely poorly documented and still weak" [2]. One controlled human insomnia pilot from 1981 reported longer, better-quality sleep in six middle-aged insomniacs [5]; follow-up was sparse and modern controlled trials essentially do not exist. A large share of people who try it report no effect at all. This page summarizes what was studied; it does not recommend DSIP and lists no human dose. ## What it is DSIP is a linear nonapeptide — nine amino acids — with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, sometimes written WAGGDASGE. Its molecular formula is C35H48N10O15. It was first characterized in 1977 by Schoenenberger and Monnier, who isolated it from the cerebral venous blood of rabbits during electrically induced sleep and showed that intraventricular infusion produced specific, measurable delta and spindle EEG enhancement in those animals [6]. A naturally occurring phosphorylated form (DSIP-P) is described in some literature and reported as more potent in certain assays. Despite the well-defined sequence, the peptide remains one of the most mechanistically uncharacterized endogenous compounds in sleep research. It crosses the blood-brain barrier — probably via a saturable transporter competitively inhibited by L-tryptophan — but where it goes next, and what it binds to, remains unestablished [2]. ## How it works The honest answer is: not clearly known. A 2006 Journal of Neurochemistry review, the most authoritative assessment of the field, concluded that despite more than forty years of study no DSIP receptor, gene, or precursor protein has ever been conclusively isolated [2]. The mechanism is genuinely unresolved. What has been observed in various models: DSIP appears to influence the hypothalamic-pituitary-adrenal (HPA) stress axis — intravenous DSIP significantly reduced plasma ACTH-like immunoreactivity in men for at least three hours after injection, while cortisol followed its normal diurnal pattern unaffected [4]. In rats, there is evidence of a dopaminergic relay for a growth-hormone effect that is sensitive to the dopamine blocker pimozide, and proposed interactions with the endogenous opioid system have been suggested by older withdrawal-syndrome pilot studies [2]. A 2024 study tested a fusion peptide engineered to improve blood-brain-barrier crossing (DSIP-CBBBP) and reported reduced wakefulness, restored monoamines, and anxiolytic effects in a mouse insomnia model, outperforming native DSIP [1] — a result that says more about the limitations of native DSIP's delivery than about its fundamental mechanism. The literature also documents a parabolic, non-monotonic dose-response: more is not reliably more effective. That is an unusual and complicating feature for any agent without an identified receptor. ## What the research shows *The founding experiment.* In 1977, Schoenenberger and Monnier isolated DSIP from sleeping-rabbit cerebral blood and showed that intraventricular infusion produced significant, specific enhancement of delta and spindle EEG activity — the signatures of slow-wave sleep [6]. This established the sequence and named the compound. *The critical review.* A 2006 Journal of Neurochemistry review by Kovalzon and Strekalova consolidated forty years of findings and arrived at a damaging verdict: no receptor, no gene, no precursor; sleep-promoting evidence "extremely poorly documented and still weak"; synthetic analogs, not native DSIP, showed the clearest activity; brain distribution was in regions not clearly relevant to sleep regulation [2]. This review is the essential counterweight to optimistic accounts. *The one human sleep pilot.* In 1981, intravenous synthetic DSIP at 25 nmol/kg improved disturbed sleep in six middle-aged chronic insomniacs: longer duration, fewer interruptions, slightly more REM, and no daytime sedation; a mild arousal appeared in the first hour before effects set in during the second [5]. Small, old, uncontrolled — but the only human controlled sleep datum that exists. *Neuroendocrine signal in people.* In 1989, intravenous DSIP at 25 nmol/kg in men produced a significant reduction in plasma ACTH-like immunoreactivity lasting at least three hours, while cortisol was unaffected and followed its normal diurnal decline [4]. The HPA-axis touch point is one of the more reproducible observations in the literature. *Longevity signal in mice.* Monthly courses of a DSIP-containing preparation (Deltaran) in female SHR mice increased maximum lifespan by 24.1%, extended the last 10% of survivors' lifespan by 17.1%, reduced total spontaneous tumor incidence 2.6-fold, and reduced bone-marrow chromosome aberrations by 22.6% [3]. Important caveat: this comes from a small set of related Russian research groups and has not been independently replicated. *Neuroprotection after stroke.* In adult male rats with a focal stroke, intranasal DSIP significantly improved motor-function recovery by day 7; infarct volume was similar between groups (20.9% vs 24.1%, not statistically significant), suggesting functional neuroprotection rather than infarct-limiting action [7]. *BBB-crossing fusion peptide.* A 2024 study in PCPA-induced insomnia mice found that DSIP engineered with a blood-brain-barrier penetrating peptide (DSIP-CBBBP) reduced average daily wakefulness by roughly 31%, restored melatonin, serotonin, and dopamine levels, produced anxiolytic and antidepressant behavioral effects, and increased hippocampal neuron density — outperforming unmodified DSIP on every measure [1]. ## Reported effects, cautions & safety The community experience with DSIP is unusually candid about its own inconsistency, which is what makes it worth reading closely. The following signals come from nootropic and peptide communities and should be treated as **anecdotal, not clinical evidence**. **What responders report:** An easier transition into sleep — a quieter mind, fewer racing thoughts, a sense of being ready for sleep rather than being forced into it. People describe it as subtle, not a sedative hit. Those who respond often say the same hours of sleep feel more restorative: less waking during the night, waking clearer and without the grogginess they associate with melatonin or sleep aids. Very vivid or memorable dreams are one of the most commonly reported features, ranging from pleasant to occasionally disruptive. **What non-responders report — the most important signal:** A large share of people report that DSIP did nothing for them. A commonly cited practitioner estimate is that it meaningfully helps roughly half of those who try it. Forums are full of "didn't notice anything" reports. Non-response is a real and common outcome, not an edge case. **Other mixed and adverse signals:** Unpredictable or delayed timing — one widely shared account describes sedation arriving the following day during work hours rather than that night. Next-day grogginess in a minority, especially with higher use. Headache is the most commonly reported side effect, usually described as mild and transient, though one forum account describes it lasting days. Mild nausea, dizziness, or lightheadedness occurs occasionally. Some report diminishing benefit with consecutive nightly use. **Cited cautions from the literature:** - *Unregulated research-chemical status.* DSIP is not an approved drug anywhere; what is in a given online vial — purity, dose, sterility — is not independently guaranteed [2]. - *Unknown mechanism means unpredictable interactions.* With no receptor identified and a parabolic dose-response, there is no sound basis for predicting how DSIP interacts with medications, supplements, or medical conditions [2]. - *Essentially no long-term human safety data.* Human studies are limited to small 1980s pilots; there is no large, long-duration controlled human safety study and no validated human pharmacokinetic profile [5]. - *Masking an undiagnosed sleep disorder.* Persistent sleep trouble can be a symptom of treatable conditions (sleep apnea, a circadian disorder, depression, thyroid problems). An unapproved peptide is not a substitute for evaluation [5]. - *Unknown safety in combination with sedatives, sleep aids, or alcohol.* A plausible CNS action exists; stacking on sedating substances has never been formally tested [2]. - *Effects in pregnancy and with pre-existing conditions are unknown* [2]. ![DSIP research illustration](/images/dsip.webp) ## Where it fits in sleep research DSIP occupies an unusual position in this field: a peptide with a compelling founding story, a natural origin, and genuine human pilot data — but also the most honestly uncertain mechanistic picture of any well-known research peptide. Its name promises more than its evidence delivers. Read alongside [Selank](/selank), which has a more fully characterized anxiolytic mechanism and a somewhat stronger (if still limited) clinical record, DSIP illustrates the central tension in this entire category: a plausible signal from the body's own chemistry that has resisted every attempt to pin it down. See the [comparison page](/compare) for how the two line up. --- A literature digest tracking the published evidence on sleep and recovery peptides — citations in, no prescriptions out.